Head-to-head · Value Score
Vitara RX vs Wisp
Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, Wisp a 75. Here's who gives you the honest lower price — and where each one bites back.
Vitara RX
#4 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameWisp
#139 · Grade C+ · Fair Price
Est. first month
From $99/mo (starting dose, brand-name)
The verdict
Vitara RX takes it on Value Score, 91 to 75 — an est. $99/mo first month, with no teaser step-up baked in. Wisp isn't out of it: Shoppers who want branded injectables plus a sublingual semaglutide alternative.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Vitara RX | Wisp |
|---|---|---|
| Value Score | 91 (A) | 75 (C+) |
| Est. first month | $99/mo | From $99/mo (starting dose, brand-name) |
| Save vs brand-name | ~93% | — |
| Semaglutide | $99/mo | From $225/mo (compounded oral) |
| Tirzepatide | $149/mo | From $99/mo (starting dose, brand-name) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | 49 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Vitara RX
VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.
Why it's a deal
- Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
- Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- Covers 49 states with an explicit state list, not vague "most states" language
The fine print
- No corporate legal entity disclosed — only the trade name "VitaraRx"
- No named medical director — all clinical decisions made by independent providers (marketplace model)
- All sales final — no medication returns
- Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
- Doesn't ship to Alaska
Wisp
Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.
Why it's a deal
- Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
- LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
- Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary
The fine print
- Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
- Pharmacy partners not named
- States served not listed publicly
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to Wisp.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.